Long Shortz with Island Pharmaceuticals: Could this be the answer to dengue fever?
Stockhead’s Fraser Palamara catches up with Island Pharmaceuticals CEO and managing director Dr David Foster.
Stockhead
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News.
Fraser Palamara speaks Island Pharmaceuticals (ASX:ILA) CEO and managing director Dr David Foster for an update on the company's Phase 2a/b PROTECT trial on its lead candidate, ISLA-101.
Island is aiming to treat dengue fever using ISLA-101, with results from the Phase 2a/b trial expected next month.
Watch the full interview to hear more.
This video was developed in collaboration with Island Pharmaceuticals.
The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.
Originally published as Long Shortz with Island Pharmaceuticals: Could this be the answer to dengue fever?
BTC strong as DigitalX ramps up staking revenue
ASX-listed DigitalX is leaning into Bitcoin’s April momentum with rising crypto infrastructure earnings and a streamlined business model.
Read more
Why digital assets are no longer just for ‘crypto bros’
Australia’s crypto landscape has shifted from niche interest to mainstream appeal, writes Kraken’s Jonathon Miller.
Read more